Triple negative breast cancer in a male-to-female transsexual

Internal Medicine Journal

Volumn 43, Issue 2, 2013, Pages 203-205

  Pattison, S T ^a   Mclaren, B R ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Southern District Health Board   (New Zealand)

Author keywords

Antipsychotic; Breast cancer; Hyperprolactinaemia; Oestrogen; Transgender

Indexed keywords

CYCLOPHOSPHAMIDE; DOXEPIN; DOXORUBICIN; PACLITAXEL; PROLACTIN;

ADULT; ARTICLE; BONE SCINTISCANNING; BORDERLINE STATE; BREAST BIOPSY; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CAUSE OF DEATH; DEATH; DRUG OVERDOSE; FEMALE; HUMAN; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; MAJOR DEPRESSION; MALE TO FEMALE TRANSSEXUAL; MEDICAL HISTORY; MEDICAL LITERATURE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SPINAL CORD METASTASIS; STERNUM;

ADULT; BREAST NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; MALE; TRANSGENDERED PERSONS;

EID: 84873707108     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12047     Document Type: Article

References (19)

1. Gooren LJ, Giltay EK, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93: 19-25.
2. Symmers WS. Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br Med J 1968; 2: 83-85.
3. Pritchard TJ, Pankowsky DA, Crow JP, Abdul-Karim FW. Breast cancer in a male-to-female transsexual. JAMA 1988; 259: 2278-2280.
4. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg 1995; 82: 341.
5. Grabellus F, Worm K, Willruth A, Schmitz KJ, Ottenbach F, Baba HA etal. ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual. Breast 2005; 14: 71-74.
6. Dhand A, Dhaliwal G. Examining patient conceptions: a case of metastatic breast cancer in an African American male-to-female transgender patient. J Gen Intern Med 2010; 25: 158-161.
7. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008; 159: 197-202.
8. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle and hormones. Breast Cancer Res Treat 2004; 6: 213-218.
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML etal. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
10. Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011; 103: 296-305.
11. Allred DC. The origins of oestrogen receptor negative breast cancer. Breast Cancer Res 2007; 9(Suppl 2): S20-S22.
12. Asscheman H, Gooren LJ, Assies J, Smits JP, de Slegte R. Prolactin levels and pituitary enlargement in male-to-female transsexuals. Clin Endocrinol (Oxf) 1988; 28: 583-588.
13. Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 2008; 22: 20-27.
14. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C etal. Plasma prolactin levels and subsequent risk of breast cancer in post menopausal women. J Natl Cancer Inst 1999; 91: 629-634.
15. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64: 6814-6819.
16. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 2006; 66: 2476-2482.
17. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R etal. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147-1154.
18. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22: 46-55.
19. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP etal. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94: 3132-3153.